Brussels, 09/12/2013 (Agence Europe) - The report on deals between patent holders and manufacturers of generic pharmaceutical products in 2012, published by the European Commission on Monday 9 December, shows that the number of deals has shot up, but there are few that cause cartel or abuse of dominant position problems. The Commission concludes from this that the pharmaceutical industry is paying greater attention to potential competition concerns which could delay the entry onto the market...